Abstract
Prior treatment with thalidomide or lenalidomide—immunomodulators widely used for first-line treatment of multiple myeloma—does not affect the safety or efficacy of use of pegylated liposomal doxorubicin (PLD) plus bortezomib in patients with recurrent or refractory multiple myeloma, according to a prespecified subgroup analysis from a phase III trial (Cancer, published online Feb 25, 2008; DOI:10.1002/cncr.23326). Of note, says first author Pieter Sonneveld (Erasmus Medical Center, Rotterdam, Netherlands), “the PLD and bortezomib combination is more effective than bortezomib alone in both immunomodulator-naive and immunomodulator-exposed patients”.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
